EcoDrugPlus

Cholecystokinin Receptor-Like

Ensembl ID : ENSNFUG00015006603
Gene Symbol: LOC107389856
3 Cross references
191 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSNFUG00015002219
Gene Symbol: LOC107381016
3 Cross references
193 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSNFUG00015003221
Gene Symbol: LOC107378150
3 Cross references
257 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSNFUG00015020995
Gene Symbol: CETP
1 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSNFUG00015023617
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSNFUG00015015939
Gene Symbol: CHRM3
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSNFUG00015002543
Gene Symbol: CHRM5
3 Cross references
189 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSNFUG00015008404
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSNFUG00015012274
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSNFUG00015006009
Gene Symbol: CHRNA7A
1 Cross references
205 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSNFUG00015014465
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSNFUG00015016260
Gene Symbol: LOC107384573
3 Cross references
78 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).